Need help finding what you are looking for?
Contact Us
PUBLISHER: DelveInsight | PRODUCT CODE: 2082768
PUBLISHER: DelveInsight | PRODUCT CODE: 2082768
Gastrointestinal Stromal Tumor (GIST) - Epidemiology Forecast - 2036
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Gastrointestinal Stromal Tumor (GIST) Insights and Trends
- GISTs can develop anywhere along the gastrointestinal tract, from the esophagus to the anus. The stomach accounts for approximately 55% of cases, making it the most common site of origin, followed by the duodenum and small intestine (30%). Less frequently, GISTs arise in the esophagus (5%), rectum (5%), and colon (2%). In rare cases, primary GISTs may develop outside the gastrointestinal tract, including the peritoneum, mesentery, omentum, liver, pancreas, ovaries, uterus, and prostate.
- GISTs comprise less than 1% of all gastrointestinal tumors but are the most common mesenchymal tumors of the gastrointestinal tract.
- GIST are classified by their risk of recurrence or progression rather than as benign or malignant. Risk assessment is based on tumor size, mitotic index, location, and mutation status. Molecular testing for Receptor Tyrosine Kinase (KIT) or Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) mutations is recommended, with SDH (succinate dehydrogenase) testing performed in tumors that are negative for both mutations.
- GIST typically presents in the gastrointestinal tract with 80% of cases driven by mutations in the KIT gene that lead to the growth, proliferation and survival of tumour cells. Around 12-15% of cases lack detectable mutations in both genes and are classified as KIT/PDGFRA wild-type (WT) GISTs. Additionally, <5% of GISTs are associated with hereditary or syndromic conditions, including neurofibromatosis type 1 (NF1), Carney triad syndrome, and other familial disorders.
- GISTs can affect patients of all ages but are most predominant in older adults (median age, 65-69 years).
- A substantial proportion of GIST patients present with advanced disease, with up to 50% exhibiting metastases or multifocal tumor involvement at diagnosis.
DelveInsight's 'Gastrointestinal Stromal Tumor (GIST) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the GIST, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Gastrointestinal Stromal Tumor (GIST) Understanding and Diagnosis Algorithm
Gastrointestinal Stromal Tumor (GIST) Overview and Diagnosis
GIST is a rare type of mesenchymal tumor of the gastrointestinal tract, most commonly arising in the stomach or small intestine. It is primarily driven by activating mutations in the KIT or PDGFRA genes, which lead to uncontrolled cell growth. Despite its rarity, reported incidence has increased in recent years due to improved diagnostic techniques and wider use of molecular testing.
Gastrointestinal Stromal Tumor (GIST) Diagnosis
Diagnosis typically involves a combination of imaging, histopathology, and molecular testing. Techniques such as CT scans and endoscopy help identify tumor location and size, while biopsy confirms the diagnosis. Immunohistochemical markers like KIT (CD117) and DOG1 are commonly used to distinguish GIST from other tumors. Genetic testing is essential to identify KIT or PDGFRA mutations, as this directly guides treatment decisions and therapy selection.
Gastrointestinal Stromal Tumor (GIST) Epidemiology
Key Findings from GIST Epidemiological Analysis and Forecast
- In 2025, the US accounted for the highest incident cases of GIST with more than 5,600 cases. These cases are anticipated to increase during the forecast period.
- The number of new cases of GISTs in the United States each year has been estimated at 5,000-6,000.
- GISTs constitute 0.1-3% of all GI neoplasms. The estimated annual incidence is 10-15 new cases per million people or approximately 3,000-5,000 new cases in the US yearly. Although GISTs may occur at all ages, the peak incidence is in the sixth decade of life, with a slight male predominance.
- In the United States, GISTs most commonly arise in the stomach (~60%) and small intestine (~35%), while a smaller proportion occur in the esophagus, colon, rectum, or, rarely, outside the gastrointestinal tract within the abdominal cavity.
- GIST is more common among males than females.
- GIST is more commonly diagnosed at the localized stage compared to other stages.
Scope of the Report:
- The report covers a segment of a descriptive overview of GIST, explaining their causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Gastrointestinal Stromal Tumor (GIST) Patient Population Forecast
Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs:
- What are the disease risks, burdens, and unmet needs of GIST? What will be the growth opportunities across the 7MM concerning the patient population with GIST?
- What is the historical and forecasted GIST patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Product Code: DIEI0084
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Epidemiology Methodology of Gastrointestinal Stromal Tumor (GIST)
5. Gastrointestinal Stromal Tumor (GIST) Epidemiology Overview at a Glance
- 5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
- 5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
6. Disease Background And Overview of Gastrointestinal Stromal Tumor (GIST)
- 6.1. Introduction
- 6.2. Causes
- 6.3. Signs And Symptoms
- 6.4. Diagnosis
- 6.4.1. Differential Diagnosis
- 6.4.2. Diagnostic Algorithm
- 6.4.3. Diagnostic Guidelines
7. Epidemiology and Patient Population of Gastrointestinal Stromal Tumor (GIST)
- 7.1. Key Findings
- 7.2. Assumption and Rationale
- 7.3. Total Prevalent Cases of Gastrointestinal Stromal Tumor (GIST) in the 7MM
- 7.4. The United States
- 7.1. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
- 7.4.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
- 7.4.4. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
- 7.4.4. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
- 7.4.5. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
- 7.4.6. Treated Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
- 7.5. EU4 and the UK
- 7.5.1. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in EU4 and the UK
- 7.5.2. Age-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in EU4 and the UK
- 7.5.3. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in EU4 and the UK
- 7.5.4. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in EU4 and the UK
- 7.5.5. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in EU4 and the UK
- 7.5.6. Treated Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
- 7.6. Japan
- 7.6.1. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in Japan
- 7.6.2. Age-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in Japan
- 7.6.3. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in Japan
- 7.6.4. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in Japan
- 7.6.5. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in Japan
- 7.6.6. Treated Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
8. Patient Jounery of Gastrointestinal Stromal Tumor (GIST)
9. KOL Views of Gastrointestinal Stromal Tumor (GIST)
10. Appendix
- 10.1. Bibliography
- 10.2. Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
Product Code: DIEI0084
List of Tables
- Table 1: Gastrointestinal Stromal Tumor (GIST) Epidemiology in 7MM (2022-2036)
- Table 2: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in 7MM (2022-2036)
- Table 3: Gastrointestinal Stromal Tumor (GIST) Epidemiology in the United States (2022-2036)
- Table 4: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in the United States (2022-2036)
- Table 5: Gastrointestinal Stromal Tumor (GIST) Epidemiology in Germany (2022-2036)
- Table 6: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Germany (2022-2036)
- Table 7: Gastrointestinal Stromal Tumor (GIST) Epidemiology in France (2022-2036)
- Table 8: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in France (2022-2036)
- Table 9: Gastrointestinal Stromal Tumor (GIST) Epidemiology in Italy (2022-2036)
- Table 10: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Italy (2022-2036)
- Table 11: Gastrointestinal Stromal Tumor (GIST) Epidemiology in Spain (2022-2036)
- Table 12: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Spain (2022-2036)
- Table 13: Gastrointestinal Stromal Tumor (GIST) Epidemiology in the United Kingdom (2022-2036)
- Table 14: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in the United Kingdom (2022-2036)
- Table 15: Gastrointestinal Stromal Tumor (GIST) Epidemiology in Japan (2022-2036)
- Table 16: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Japan (2022-2036)
The list of table is not exhaustive; will be provided in the final report
List of Figures
- Figure 1: Gastrointestinal Stromal Tumor (GIST) Epidemiology in 7MM (2022-2036)
- Figure 2: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in 7MM (2022-2036)
- Figure 3: Gastrointestinal Stromal Tumor (GIST) Epidemiology in the United States (2022-2036)
- Figure 4: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in the United States (2022-2036)
- Figure 5: Gastrointestinal Stromal Tumor (GIST) Epidemiology in Germany (2022-2036)
- Figure 6: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Germany (2022-2036)
- Figure 7: Gastrointestinal Stromal Tumor (GIST) Epidemiology in France (2022-2036)
- Figure 8: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in France (2022-2036)
- Figure 9: Gastrointestinal Stromal Tumor (GIST) Epidemiology in Italy (2022-2036)
- Figure 10: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Italy (2022-2036)
- Figure 11: Gastrointestinal Stromal Tumor (GIST) Epidemiology in Spain (2022-2036)
- Figure 12: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Spain (2022-2036)
- Figure 13: Gastrointestinal Stromal Tumor (GIST) Epidemiology in the United Kingdom (2022-2036)
- Figure 14: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in the United Kingdom (2022-2036)
- Figure 15: Gastrointestinal Stromal Tumor (GIST) Epidemiology in Japan (2022-2036)
- Figure 16: Gastrointestinal Stromal Tumor (GIST) Diagnosed and Treatable Cases in Japan (2022-2036)
The list of figures is not exhaustive; will be provided in the final report
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.